2026 Global: Allergy Immunotherapy-Competitive Review (2032) report
Description
The 2026 Global: Allergy Immunotherapy-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for allergy immunotherapy by geography and historical trend. The scope of the report extends to sizing of the allergy immunotherapy market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
ALK‑Abelló A/S, Stallergenes Greer, Allergy Therapeutics plc, HAL Allergy Group and DBV Technologies are among the ten major companies shaping allergy immunotherapy through portfolios that span subcutaneous and sublingual extracts, food‑allergy oral immunotherapies and novel delivery platforms. ALK‑Abelló is a longstanding leader in venom and respiratory allergen extracts and immunotherapy services with broad geographic reach and digital allergy care tools. Stallergenes Greer consolidated its position after acquiring Aimmune/Nestlé’s PALFORZIA business and continues to market allergen extracts and SCIT products while expanding pediatric food‑allergy support programs. Allergy Therapeutics focuses on standardized biological extracts and sublingual tablets for rhinitis and venom allergies, leveraging long clinical experience in Europe. HAL Allergy Group supplies allergen extracts and diagnostic reagents and partners frequently on regional manufacturing and formulation scale‑up. DBV Technologies pursues epicutaneous immunotherapy (EPIT) with its Viaskin patch platform for peanut and other food allergies, aiming to provide needle‑free, home‑based desensitization options.
Genentech (Roche), Novartis, Sanofi and Regeneron contribute to allergy immunotherapy chiefly through biologics and combination strategies that augment or enable safer oral immunotherapy (OIT) protocols. Genentech’s work with omalizumab and other anti‑IgE strategies has shown facilitation of higher OIT thresholds and improved safety profiles in trials. Novartis and Sanofi develop monoclonal antibodies and cytokine‑targeting agents intended to reduce allergic inflammation and serve as adjuncts to desensitization regimens, while Regeneron’s dupilumab and allied programs explore indications that overlap food and respiratory allergy mechanisms. These large pharma players also invest in manufacturing scale, biosimilars and global market access to support wider adoption of biologic‑assisted immunotherapy. Smaller specialized firms such as Circassia, ASIT Biotech and Immunomic (and other clinical‑stage innovators) advance peptide‑based vaccines, intradermal or intralymphatic approaches, and adjuvanted formulations aimed at shortening treatment duration, improving durability of tolerance and expanding indications beyond seasonal rhinitis to multi‑allergen and food allergy populations.
Commercial dynamics are driven by regulatory approvals, reimbursement for OIT and biologics, and the push for patient‑friendly delivery formats such as patches, sublingual tablets and home‑based dosing supported by telehealth and adherence platforms. Market reports identify ALK‑Abelló, Stallergenes Greer, HAL Allergy and Allergy Therapeutics as legacy extract manufacturers while DBV, Circassia and ASIT represent technology‑focused challengers; Genentech, Novartis, Sanofi and Regeneron supply biologic adjuncts and pipeline depth that accelerate clinical adoption and combination strategies. Competitive pressures include biosimilar entry for omalizumab‑class drugs, consolidation to secure manufacturing capacity, and partnerships that pair immunotherapy products with digital monitoring or diagnostics to improve safety, uptake and long‑term tolerance outcomes.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for allergy immunotherapy by geography and historical trend. The scope of the report extends to sizing of the allergy immunotherapy market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
ALK‑Abelló A/S, Stallergenes Greer, Allergy Therapeutics plc, HAL Allergy Group and DBV Technologies are among the ten major companies shaping allergy immunotherapy through portfolios that span subcutaneous and sublingual extracts, food‑allergy oral immunotherapies and novel delivery platforms. ALK‑Abelló is a longstanding leader in venom and respiratory allergen extracts and immunotherapy services with broad geographic reach and digital allergy care tools. Stallergenes Greer consolidated its position after acquiring Aimmune/Nestlé’s PALFORZIA business and continues to market allergen extracts and SCIT products while expanding pediatric food‑allergy support programs. Allergy Therapeutics focuses on standardized biological extracts and sublingual tablets for rhinitis and venom allergies, leveraging long clinical experience in Europe. HAL Allergy Group supplies allergen extracts and diagnostic reagents and partners frequently on regional manufacturing and formulation scale‑up. DBV Technologies pursues epicutaneous immunotherapy (EPIT) with its Viaskin patch platform for peanut and other food allergies, aiming to provide needle‑free, home‑based desensitization options.
Genentech (Roche), Novartis, Sanofi and Regeneron contribute to allergy immunotherapy chiefly through biologics and combination strategies that augment or enable safer oral immunotherapy (OIT) protocols. Genentech’s work with omalizumab and other anti‑IgE strategies has shown facilitation of higher OIT thresholds and improved safety profiles in trials. Novartis and Sanofi develop monoclonal antibodies and cytokine‑targeting agents intended to reduce allergic inflammation and serve as adjuncts to desensitization regimens, while Regeneron’s dupilumab and allied programs explore indications that overlap food and respiratory allergy mechanisms. These large pharma players also invest in manufacturing scale, biosimilars and global market access to support wider adoption of biologic‑assisted immunotherapy. Smaller specialized firms such as Circassia, ASIT Biotech and Immunomic (and other clinical‑stage innovators) advance peptide‑based vaccines, intradermal or intralymphatic approaches, and adjuvanted formulations aimed at shortening treatment duration, improving durability of tolerance and expanding indications beyond seasonal rhinitis to multi‑allergen and food allergy populations.
Commercial dynamics are driven by regulatory approvals, reimbursement for OIT and biologics, and the push for patient‑friendly delivery formats such as patches, sublingual tablets and home‑based dosing supported by telehealth and adherence platforms. Market reports identify ALK‑Abelló, Stallergenes Greer, HAL Allergy and Allergy Therapeutics as legacy extract manufacturers while DBV, Circassia and ASIT represent technology‑focused challengers; Genentech, Novartis, Sanofi and Regeneron supply biologic adjuncts and pipeline depth that accelerate clinical adoption and combination strategies. Competitive pressures include biosimilar entry for omalizumab‑class drugs, consolidation to secure manufacturing capacity, and partnerships that pair immunotherapy products with digital monitoring or diagnostics to improve safety, uptake and long‑term tolerance outcomes.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.